The Voltage Dependent Anion Selective Channel Protein 1 pipeline drugs market research report outlays comprehensive information on the Voltage Dependent Anion Selective Channel Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Voltage Dependent Anion Selective Channel Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Metabolic Disorders, and Cardiovascular which include the indications Alzheimer’s Disease, Neurodegenerative Diseases, Glaucoma, Dry (Atrophic) Macular Degeneration, Type 2 Diabetes, and Myocardial Infarction. It also reviews key players involved in Voltage Dependent Anion Selective Channel Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Voltage Dependent Anion Selective Channel Protein 1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 2 respectively.
Voltage Dependent Anion Selective Channel Protein 1 overview
Voltage-dependent anion-selective channel 1 (VDAC-1) is a beta barrel protein that in humans is encoded by a gene VDAC1. This protein is a major component of the outer mitochondrial membrane (OMM) and forms an ion channel in the OMM and the outer cell membrane. The encoded protein facilitates the exchange of metabolites and ions across the outer mitochondrial membrane and may regulate mitochondrial functions. This protein also forms channels in the plasma membrane and may be involved in transmembrane electron transport.
For a complete picture of Voltage Dependent Anion Selective Channel Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
